Market Research Logo

Raynauds Disease - Pipeline Review, H2 2016

Raynauds Disease - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Raynauds Disease - Pipeline Review, H2 2016’, provides an overview of the Raynauds Disease pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Raynauds Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Raynauds Disease and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape of Raynauds Disease
    • The report reviews pipeline therapeutics for Raynauds Disease by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved Raynauds Disease therapeutics and enlists all their major and minor projects
    • The report assesses Raynauds Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news related to pipeline therapeutics for Raynauds Disease
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand important and diverse types of therapeutics under development for Raynauds Disease
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Raynauds Disease pipeline depth and focus of Indication therapeutics
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


    Introduction
    Global Markets Direct Report Coverage
    Raynauds Disease Overview
    Therapeutics Development
    Pipeline Products for Raynauds Disease - Overview
    Raynauds Disease - Therapeutics under Development by Companies
    Raynauds Disease - Pipeline Products Glance
    Late Stage Products
    Clinical Stage Products
    Early Stage Products
    Raynauds Disease - Products under Development by Companies
    Raynauds Disease - Companies Involved in Therapeutics Development
    Allergan Plc
    Apricus Biosciences, Inc.
    Covis Pharmaceuticals, Inc.
    Human Stem Cells Institute
    Raynauds Disease - Therapeutics Assessment
    Assessment by Monotherapy Products
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Drug Profiles
    acetylcysteine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    alprostadil - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ELS-140 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Neovasculgen - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    nitroglycerin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    onabotulinumtoxin A - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Raynauds Disease - Dormant Projects
    Raynauds Disease - Discontinued Products
    Raynauds Disease - Product Development Milestones
    Featured News & Press Releases
    Mar 08, 2016: Apricus Biosciences to Present at the 28th Annual ROTH Conference
    Feb 02, 2016: Apricus Biosciences to Present at the 18th Annual BIO CEO & Investor Conference, Provide Update on Vitaros
    Aug 05, 2015: Apricus Biosciences to Provide Update On The European Launch of Vitaros at the Canaccord Genuity 35th Annual Growth Conference
    Apr 28, 2015: Apricus Biosciences to Present at Two Investor Conferences in May
    Jan 27, 2015: Apricus Biosciences Announces Issuance of U.S. Patent for RayVa
    Dec 04, 2014: Apricus Biosciences Announces First Patient Enrolled In Phase 2a Clinical Trial For RayVa In Patients With Raynaud's Phenomenon
    Oct 13, 2014: Apricus Biosciences Announces Notice of Allowance of U.S. Patent Application for RayVa
    Oct 01, 2014: Apricus Biosciences to Present at the 13th Annual BIO Investor Forum
    May 12, 2014: Apricus Biosciences Receives FDA Clearance to Begin Clinical Trial of RayVa for Secondary Raynaud's Phenomenon
    Dec 13, 2012: MediQuest Therapeutics To Conduct Meetings At J.P. Morgan Conference Regarding Phase III Topical Formulation Vascana
    May 31, 2011: Apricus Bio Receives Israeli Patent For RayVa For Raynaud's Phenomenon
    Apr 13, 2011: Apricus Bio Files For Orphan Drug Designation For RayVa
    Sep 22, 2010: FDA Guides Apricus Bio On RayVa's Approvability For Raynaud's Syndrome Secondary To Scleroderma
    Jan 10, 2006: MediQuest Therapeutics Receives Special Protocol Assessment From The U.S. FDA
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer
    List of Tables
    Number of Products under Development for Raynauds Disease, H2 2016
    Number of Products under Development by Companies, H2 2016
    Comparative Analysis by Late Stage Development, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Development, H2 2016
    Products under Development by Companies, H2 2016
    Raynauds Disease - Pipeline by Allergan Plc, H2 2016
    Raynauds Disease - Pipeline by Apricus Biosciences, Inc., H2 2016
    Raynauds Disease - Pipeline by Covis Pharmaceuticals, Inc., H2 2016
    Raynauds Disease - Pipeline by Human Stem Cells Institute, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Stage and Target, H2 2016
    Number of Products by Stage and Mechanism of Action, H2 2016
    Number of Products by Stage and Route of Administration, H2 2016
    Number of Products by Stage and Molecule Type, H2 2016
    Raynauds Disease - Dormant Projects, H2 2016
    Raynauds Disease - Discontinued Products, H2 2016
    List of Figures
    Number of Products under Development for Raynauds Disease, H2 2016
    Number of Products under Development by Companies, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Targets, H2 2016
    Number of Products by Stage and Targets, H2 2016
    Number of Products by Mechanism of Actions, H2 2016
    Number of Products by Stage and Mechanism of Actions, H2 2016
    Number of Products by Routes of Administration, H2 2016
    Number of Products by Stage and Routes of Administration, H2 2016
    Number of Products by Molecule Types, H2 2016
    Number of Products by Stage and Molecule Types, H2 2016

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report